Medscape www.medscape.com

References for:
Successful Islet Transplantation: Continued Insulin Reserve Provides Long-Term Glycemic Control

[Diabetes 51(7):2148-2157, 2002. © 2002 American Diabetes Association, Inc.]

  1. Soria B, Skoudy A, Martin F: From stem cells to beta cell: new strategies in cell therapy of diabetes mellitus. Diabetologia 44:407-415, 2001
  2. White SA, James, RFL, Swift SM, Kimber RM, Nicholson ML: Human islet cell transplantation: future prospects. Diabet Med 18:78-103, 2001
  3. Shapiro AMJ, Lakey JRT, Ryan EA, Korbutt GS, Toth EL, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238, 2000
  4. Ryan EA, Lakey JRT, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AMJ: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710-719, 2001
  5. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644-655, 1970
  6. Ricordi C, Lacy PE, Scharp DW: Automated islet isolation from human pancreas. Diabetes 38 (Suppl. 1):140-142, 1989
  7. Lakey JRT, Warnock GL, Shapiro AMJ, Korbutt GS, Ao Z, Kneteman NM, Rajotte RV: Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 8:285-292, 1999
  8. Linetsky E, Bottino R, Lehmann R, Alejandro R, Inverardi L, Ricordi C: Improved human islet isolation using a new enzyme blend, liberase. Diabetes 46:1120-1123, 1997
  9. Ricordi C, Gray DW, Hering BJ, Kaufman DB, Warnock GL, Kneteman NM, Lake SP, London NJ, Alejandro R, Zeng Y, Scharp D, Viviani G, Falqui L, Tzakis A, Bretzel R, Federlin K, Pozza G, James RFL, Rajotte R, DiCarlo V, Morris PJ, Sutherland DER, Starzl T, Mintz DH, Lacy P: Islet isolation assessment in man and large animals. Acta Diabetol Lat 27:185-195, 1990
  10. Levy JC, Mathews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192, 1998
  11. Weimar B, Rauber K, Brendel MD, Bretzel RG, Rau WS: Percutaneous transhepatic catheterization of the portal vein: a combined CT- and fluoroscopy-guide technique. Cardiovasc Intervent Radiol 22:342-344, 1999
  12. de Mattos AM, Olyaei AJ, Bennett WM: Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kid Dis 35:333-346, 2000
  13. Lauritzen T, Frost-Larsen K, Larsen H-W, Deckert T: Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet i:200-204, 1983
  14. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O: Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ 290:811-815, 1985
  15. Kahan BD, Kramer WG: Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharmacol Ther 70:74-81, 2001
  16. Bosi E, Braghi S, Maffi P, Scirpoli M, Bertuzzi F, Pozza G, Secchi A, Bonifacio E: Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 50:2464-2471, 2001
  17. Dmitrewski J, Krentz AJ, Mayer AD, Buckels JA, Barnes AD, Smith J, Nattrass M: Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation. Diab Obes Metab 3:287-292, 2001
  18. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP: Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 12:583-588, 2001
  19. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimitriou JC: Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 68:396-402, 1999
  20. Luzi L, Perseghin G, Brendel MD, Terruzzi I, Battezzati A, Eckhard M, Brandhorst D, Brandhorst H, Friemann S, Socci C, Di Carlo V, Sereni LP, Benedini S, Secchi A, Pozza G, Bretzel RG: Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients. Diabetes 50:277-282, 2001
  21. Brendel MD, Hering BJ, Schulz AO, Bretzel RG: International Islet Transplant Registry Report. Giessen, Germany, University of Giessen, 1999, p.1-20
  22. Benhamou PY, Oberholzer J, Toso C, Kessler L, Penfornis A, Bayle F, Thivolet C, Martin X, Ris F, Badet L, Colin C, Morel P: Human islet transplantation network for the treatment of type 1 diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000). Diabetologia 44:859-864, 2001
  23. Korc M: Normal function of the endocrine pancreas. In The Pancreas. Go VLW, Dimagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, Eds. New York, Raven Press, 1993, p.751-758
  24. Volk BW, Wellmann KF: Quantitative studies of the islets of nondiabetic patients. In The Diabetic Pancreas. Volk BW, Arquilla ER, Eds. New York, Plenum Medical, 1985, p.117-125
  25. Teuscher AU, Kendall DM, Smets YFC, Leone JP, Sutherland DER, Robertson RP: Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 47:324-330, 1998
  26. Blachier F, Mourtada A, Sener A, Malaisse WJ: Stimulus-secretion coupling of arginine-induced insulin release: uptake of metabolized and nonmetabolized cationic aminoacids by pancreatic islets. Endocrinology 124:134-141, 1989
  27. Bardet S, Rohmer V, Maugendre D, Marre M, Semana G, Limal JM, Allannic H, Charbonnel B, Sai P: Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34:648-654, 1991
  28. Ganda OP, Srikanta S, Brink SJ, Morris MA, Gleason RE, Soeldner JS, Eisenbarth GS: Differential sensitivity to beta-cell secretagogues in "early," type 1 diabetes mellitus. Diabetes 33:516-521, 1984
  29. Palmer JP, Benson JW, Walter RM, Ensinck JW: Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest 58:565-570, 1976
  30. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer JP: Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons. Diabetes 40:673-679, 1991
  31. Tobin BW, Lewis JT, Chen DZX, Finegood DT: Insulin secretory function in relation to transplanted islet mass in STZ-induced diabetic rats. Diabetes 42:98-105, 1993
  32. Davalli AM, Maffi P, Socci C, Sanvito F, Preshci M, Bertuzzi F, Falqui L, Di Carlo V, Pozza G, Secchi A: Insights from a successful case of intrahepatic islet transplantation into a type 1 diabetic patient. J Clin Endocrinol Metab 85:3847-3852, 2000
  33. Moore A, Bonner-Weir S, Weissleder R: Noninvasive in vivo measurements of beta-cell mass in mouse model of diabetes. Diabetes 50:2231-2236, 2001